CuspAI vs Figma
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $100M Series A (Sep 2025) at $520M valuation led by Temasek and NEA with NVIDIA. Kemira strategic partnership. 20x contract value growth in 21 months. Materials discovery in 6 months vs. a decade.
About
CuspAI is building the search engine for materials — an AI platform where researchers input desired material properties and receive novel chemical compositions within days rather than decades of traditional experimental synthesis. The company raised $100 million in Series A financing at a $520 million valuation in September 2025, led by Temasek and NEA with NVIDIA as a strategic co-investor. CuspAI has demonstrated full-cycle materials discovery in 6 months versus the decade-long timelines of traditional research, with contract value growing 20x in 21 months.
Dominant browser-based collaborative UI design platform at ~$600M ARR and $12.5B valuation; Adobe's $20B acquisition blocked by regulators in 2023, Figma remains independent competing with Sketch and Adobe.
About
Figma is a San Francisco-based collaborative web-based product design platform that has become the dominant tool for UI/UX designers and product teams — enabling real-time multi-user collaboration on interface design, prototyping, and design system management directly in the browser without installing desktop software. Founded in 2012 by Dylan Field and Evan Wallace and backed by Sequoia, Greylock, and Andreessen Horowitz with over $330 million raised, Figma generated approximately $600 million in ARR in 2023, serving 4 million+ designers and product teams at companies including Microsoft, Airbnb, Twitter, and Uber. Adobe announced a $20 billion acquisition offer in 2022, which was blocked by regulators in 2023 — Figma remains independent.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.